Develops drugs for diabetes, cancer, and autoimmune diseases.
Jun 2026Revenue $79.7B/yrExpenses $46.1B/yr
No trend
Figures by year
Is ELI LILLY & profitable?
Yes. In the 12 months to Jun 2026, revenue was $79.7B and expenses $46.1B.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Dec 2025 | $65.2B | $39.4B | $25.7B |
| Dec 2024 | $45.0B | $32.4B | $12.7B |
| Dec 2023 | $34.1B | $27.6B | $6.55B |
| Dec 2022 | $28.5B | $21.7B | $6.81B |
| Dec 2021 | $28.3B | $22.2B | $6.16B |
| Dec 2020 | $24.5B | $17.3B | $7.23B |
| Dec 2019 | $22.3B | $17.1B | $5.27B |
| Dec 2018 | $21.5B | $17.8B | $3.68B |
| Dec 2017 | $20.0B | $17.7B | $2.30B |
| Dec 2016 | $21.2B | $17.8B | $3.37B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.